Fig. 2: ELI-002 2P treatment results in tumor biomarker reduction and clearance.

a, Best overall tumor biomarker response for study participants reported as percentage of the baseline value. Responses are annotated for patient number, dose cohort, participant tumor type, KRAS mutation, tumor biomarker type and presence or absence of previously reported mKRAS-responsive HLA class I and II. * Patient 16 underwent excisional biopsy to assess iRECIST, and T cell infiltrate was observed; a contribution to ctDNA clearance could not be ruled out. ‘S’ indicates that the patient underwent splenectomy. b, Swimmer plot supervised by T cell response (maximum fold change from baseline; top: ≥median; bottom: <median) showing time from surgery to start of ELI-002 2P (left) and time from start of ELI-002 2P to endpoint (right; data cutoff or death), n = 25. Bar color indicates best overall tumor biomarker response for each patient. Symbols annotate the timing of completion of prime and boost immunizations, the start of subsequent therapy, iCPD, the most recent date of censor for RFS (the date of the most recent radiographic scan before the date of subsequent therapy, the data cutoff or the date of death) and the date of death where applicable. Arrows indicate ongoing treatment or ongoing follow-up. iCPD, immune confirmed progressive disease.